Overview
ASTH market data
Price History
ASTH price chart
Valuation & Profitability
- P/E (TTM)
- 60.49 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.46 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.02 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 0.1% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 0.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $18.08 – $51.60 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.8B · P/B 1.60 · P/S 0.52.
Company News
Truist Securities Maintains Buy on Astrana Health, Raises Price Target to $55Benzinga · Aug 11, 2026, 5:31 PM
Barclays Maintains Overweight on Astrana Health, Raises Price Target to $53Benzinga · Aug 7, 2026, 10:41 AM
Astrana Health Sees Q3 Sales $1.000B-$1.030B vs $1.021B EstBenzinga · Aug 6, 2026, 8:26 PM
Astrana Health Affirms FY2026 Sales Guidance of $3.800B-$4.100B vs $4.001B EstBenzinga · Aug 6, 2026, 8:26 PM
Astrana Health Q2 EPS $0.40 Beats $0.34 Estimate, Sales $972.520M Miss $985.716M EstimateBenzinga · Aug 6, 2026, 8:14 PM
TD Cowen Maintains Buy on Astrana Health, Raises Price Target to $50Benzinga · Jul 14, 2026, 3:21 PM
BTIG Maintains Buy on Astrana Health, Raises Price Target to $65Benzinga · Jul 14, 2026, 9:49 AM
8-K filing — Astrana Health, Inc. (ASTH)SEC EDGAR · Jul 13, 2026, 12:05 PM
BTIG Reiterates Buy on Astrana Health, Maintains $50 Price TargetBenzinga · Jun 2, 2026, 10:12 AM
Barclays Upgrades Astrana Health to Overweight, Raises Price Target to $50Benzinga · May 26, 2026, 6:55 PM